CoChat
Sign Up
Cited by 371Menopause: Health Impacts and TreatmentsDementia and Cognitive Impairment ResearchEstrogen and related hormone effects

The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.

Estrogen use, APOE, and cognitive decline: Evidence of gene–environment interaction

Yaffe, K., Haan, M., Byers, A., Tangen, C., Kuller, L.·2000·Neurology
DOI 10.1212/wnl.54.10.1949
Open this paper in CoChat — free account

Abstract

OBJECTIVE: APOE-epsilon4 increases the risk of cognitive decline, while elderly women who take estrogen may have less risk of cognitive decline. The authors sought to determine whether estrogen use modifies the association between APOE-epsilon4 and cognitive decline. METHOD: - As part of the Cardiovascular Health Study, 3,393 Medicare-eligible women (> or =65 years) were randomly selected and recruited from Sacramento County, CA; Washington County, MD; Forsyth County, NC; and Pittsburgh, PA. Cognitive testing was administered annually; the authors studied the 2,716 women with cognitive testing on > or =2 visits. They analyzed change in score on the Modified Mini-Mental State Examination (3MS) as a function of estrogen use, APOE genotype, and baseline common and internal carotid artery wall thickening. RESULTS: A total of 297 (11%) women were current estrogen users and 336 (12%) were past estrogen users. Over the 6-year average follow-up, baseline current users declined 1.5 points on the 3MS whereas never users declined 2.7 points (p = 0.023). Compared with epsilon4-negative women, epsilon4-positive women had a greater adjusted hazard ratio of cognitive impairment (3MS < 80), hazard risk [HR] = 1.47; 95% CI, 1.13 to 1.90. There was an interaction between estrogen use and epsilon4 presence (p = 0.037). Among epsilon4-negative women, current estrogen use reduced the risk of adjusted cognitive impairment compared with never users by almost half (HR = 0.59; 95% CI, 0.36 to 0.99), whereas, it did not reduce the risk among epsilon4-positive women (current use, HR = 1.33; 95% CI, 0.74 to 2.42). Compared with never use, current estrogen use was associated with less internal and common carotid wall thickening in epsilon4-negative women but not in epsilon4-positive women (p for interaction < 0.05 for both). Differences remained after adjusting for age, education, race, and stroke. CONCLUSIONS: Estrogen use was associated with less cognitive decline among epsilon4-negative women but not epsilon4-positive women. Potential mechanisms, including carotid atherosclerosis, by which epsilon4 may interact with estrogen and cognition warrant further investigation.

Overview

Integrity signals

Registry

Crossref · 10.1212/wnl.54.10.1949

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 35 references

Cited by

Sorted by citations

Items 201–300 of 371

Related

See all

Metadata

Authors
Yaffe, K., Haan, M., Byers, A., Tangen, C., & Kuller, L.
Affiliations
University of Pittsburgh (US)
ORCID
Venue
Neurology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2000-05-23
Volume
54
Issue
10
Pages
1949-1954
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
DOI
10.1212/wnl.54.10.1949
OpenAlex
W2004602458
Cited by
371
References
35
Citations by year
2026: 15 · 2025: 20 · 2024: 18 · 2023: 11 · 2022: 12 · 2021: 17 · 2020: 13 · 2019: 13 · 2018: 10 · 2017: 5 · 2016: 9 · 2015: 7 · 2014: 7 · 2013: 14 · 2012: 9
FWCI
17.16
Type
journal article
Language
en
Open access
closed
Locations
  • Neurology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (n01hc085083-027)
  • National Institute on Aging (K23AG000888, K23-AG 00888)
  • National Heart, Lung, and Blood Institute (N01HC-85083)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Keywords
estrogen use, APOE ε4, cognitive decline, cognitive impairment, postmenopausal women, carotid artery wall thickening, carotid atherosclerosis, gene-environment interaction, cardiovascular risk factors, older women
MeSH terms
Aged, Alzheimer Disease, Apolipoproteins E, Female, Genotype, Humans, Mental Status Schedule, Neuropsychological Tests, Risk Factors, Estrogen Replacement Therapy, Carotid Stenosis, Apolipoprotein E4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review